PLGA Nanoparticles for Oral Delivery: Nephrotoxicity and Pharmacokinetic Studies

Singh, Neelu; Mishra, Nidhi; Raza, Kaisar; Parashar, Poonam

doi:10.1007/978-3-030-83395-4_18

Cited by 2 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In comparison to estradiol alone, microdialysis demonstrated that apremilast plus estrogen decreased extracellular VEGF in solid MCF-7 tumors in nude mice. Extracellular VEGF release in vitro supported in situ findings (17)(18)(19).…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

2023

JPTCP

View full text Add to dashboard Cite

It is widely accepted that vascular endothelial growth factor, often abbreviated as VEGF, is an important mediator in the process of tumor angiogenesis, which includes neovascularization in human breast cancer. Patients with either node-positive or node-negative breast cancer have a worse prognosis overall if there are high levels of VEGF in the tissue. It would seem logical to expect a poor prognosis given these circumstances. There is evidence that the partial estrogen receptor agonist apremilast may increase the quantity of VEGF mRNA that is generated in breast cancer cells, suggesting that hormones may regulate the amount of VEGF that is expressed. However, the findings of clinical studies show that apremilast increases average survival rates while reducing the incidence of metastases. These results seem to raise questions about apremilast's efficacy as an adjuvant treatment for estrogen-dependent breast cancer. In this study, we demonstrate for the first time that apremilast can lower extracellular VEGF levels in vivo using solid MCF-7 tumors in naked mice. Nothing like to this has ever been done. Following the injection of apremilast, the levels of extracellular VEGF seen in the cell culture conditions were dramatically decreased. The in vivo outcomes that were found were supported by these findings.

show abstract

Section: Discussionsupporting

confidence: 66%

“…The significance of this cleavage in proteolytic cancers is unknown. Tumor angiogenesis and matrix metalloproteinase activity are related (19). A more accurate image of the bioactive protein released by the tumor may be obtained using microdialysis or other direct method of evaluating VEGF in the tumor (20,21).…”

Section: Discussionmentioning

confidence: 99%

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

2023

JPTCP

View full text Add to dashboard Cite

show abstract

Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms

Wagh,

Bhattacharya

2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

PLGA Nanoparticles for Oral Delivery: Nephrotoxicity and Pharmacokinetic Studies

Cited by 2 publications

References 64 publications

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

Apremilast Treatment of Cancer in Mice Tumorised with Breast Cancer: In Vivo Study

Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms

Contact Info

Product

Resources

About